Physician profile
Fernanda Scala
NPI 1568043743
$2,727.03
in general payments reported to CMS, 2019-2025
11 companies · $627 in 2025
The $627 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,703 · 2023: $46.86 · 2024: $350 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $655 · Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $654.98 |
| Food and Beverage | $368.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,577.18 | 2022 | |
| Medical Device Business Services, INC. | $654.98 | 2024-2025 | Mentor Memorygel Breast Implant, Mentor Memorygel Resterilizable Gel Sizer |
| Abbvie INC. | $193.67 | 2025 | |
| Stryker Corporation | $141.02 | 2022-2025 | Na |
| Integra Lifesciences Corporation | $34.99 | 2022 | |
| Telix Pharmaceuticals | $26.76 | 2022 | |
| Sumitomo Pharma America, INC. | $25.67 | 2023 | Gemtesa |
| Pacira Pharmaceuticals Incorporated | $22.37 | 2025 | Exparel |
| Biotissue Holdings INC. | $21.19 | 2023 | |
| Polynovo North America LLC | $16.98 | 2025 | Novosorb Btm |
| Astrazeneca Pharmaceuticals LP | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernanda Scala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.